Clinical trials: Kidney (Renal Cell) Cancer
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neoplasms, Neoplasms, Glandular and Epithelial
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK)…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02909452
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Kidney Cancer, Metastatic Cancer
Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases
RATIONALE: Radiofrequency ablation uses high-frequency electric current to heat and kill tumor cells. Magnetic resonance imaging-guided radiofrequency ablation may an effective treatment for primary kidney cancer, liver…
- Conditions
- Kidney Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006255
- Testing
- radiofrequency ablation, thermal ablation therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Renal Cell Cancer
WIRE - Novel Treatments in Renal Cell Cancer
Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when different IMPs are given as monotherapy or as combination therapy.
- Trial name
- WIRE (NCT03741426)
- Testing
- Olaparib, Cediranib, Volrustomig
- Where
- 7 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- CCTU- Cancer Theme
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Hematuria, Urothelial Carcinoma
Urine DNA Methylation Detection for Hematuria Evaluation
Background: Hematuria, a common symptom of urinary system diseases, can result from various causes including infection, stones, trauma, and tumors.
- Conditions
- Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT06427993
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Changhai Hospital
Mesothelioma, Uveal Melanoma
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
- Conditions
- Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03207347
- Testing
- Niraparib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Florida
Renal Cell Carcinoma
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated…
- Trial name
- CheckMate 374 (NCT02596035)
- Testing
- Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Trifecta Achievement, Pentafecta Achievement
Trifecta Achievement in Open and Laparoscopic Partial Nephrectomy
Background: Partial nephrectomy (PN) is a reference standard for the management of the cT1 renal mass, primarily due to better preservation of renal function.
- Trial name
- Trifecta (NCT06960135)
- Testing
- open partial nephrectomy, laparoscopic partial nephrectomy
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- South Valley University
Renal Cell Carcinoma (Kidney Cancer)
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
- Trial name
- NCT07062549
- Testing
- 111In-XYIMSR-01
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kidney Tumors Treated With Minimally Invasive Surgery
Partial Nephrectomy in Low Pressure
The main objective is to prospectively assess the impact of low insufflation pressure using AirSeal system (7mm Hg) during RAPN on post-operative patient pain (main location and intensity), 24 hours after surgery.
- Trial name
- P-NeLoP (NCT05404685)
- Testing
- Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy, Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy
- Where
- 15 sites in France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Bordeaux
Attention Deficit Disorder With Hyperactivity, Asthma
Study of an Intervention to Improve Problem List Accuracy and Use
The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer
- Trial name
- MAPLE (NCT01105923)
- Testing
- MAPLE
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Brigham and Women's Hospital
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Renal Cell Carcinoma, Kidney Cancer
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.
- Conditions
- Renal Cell Carcinoma, Kidney Cancer, Adenocarcinoma of Kidney, Adenocarcinoma, Renal
- Trial name
- NCT04260360
- Testing
- NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
- Sponsor
- NanOlogy, LLC
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on…
- Trial name
- SPAZO (NCT02282579)
- Testing
- Pazopanib
- Where
- 34 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris